Alkermes plc. Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent
Alkermes plc. (ALKS) reported Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent of $0 for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-10-28.
Financial Statements › Income Statement › Net Income
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity · last filed 2026-02-25
- Alkermes plc. income (loss) from discontinued operations, net of tax, attributable to parent for the quarter ending 2025-09-30 was $0.00.
- Alkermes plc. income (loss) from discontinued operations, net of tax, attributable to parent for the quarter ending 2025-06-30 was $0.00.
- Alkermes plc. income (loss) from discontinued operations, net of tax, attributable to parent for the quarter ending 2025-03-31 was $0.00.
- Alkermes plc. income (loss) from discontinued operations, net of tax, attributable to parent for the quarter ending 2024-12-31 was $766.00K.
- Alkermes plc. income (loss) from discontinued operations, net of tax, attributable to parent for fiscal 2024 was -$5.07M.
- Alkermes plc. income (loss) from discontinued operations, net of tax, attributable to parent for fiscal 2023 was -$163.40M.
- Alkermes plc. income (loss) from discontinued operations, net of tax, attributable to parent for fiscal 2022 was -$125.11M.
- Alkermes plc. income (loss) from discontinued operations, net of tax, attributable to parent for fiscal 2021 was -$124.57M.
| Period end | Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent 3 month | Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent 6 month | Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent 9 month | Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-10-28 | $0.00 derived: sum of 2 quarters · filed 2025-10-28 | $0.00 10-Q · filed 2025-10-28 | $766.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2025-06-30 | $0.00 10-Q · filed 2025-07-29 | $0.00 10-Q · filed 2025-07-29 | $766.00K derived: sum of 3 quarters · filed 2026-02-25 | $352.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-01 | $766.00K derived: sum of 2 quarters · filed 2026-02-25 | $352.00K derived: sum of 3 quarters · filed 2026-02-25 | -$2.95M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-12-31 | $766.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $352.00K derived: sum of 2 quarters · filed 2026-02-25 | -$2.95M derived: sum of 3 quarters · filed 2026-02-25 | -$5.07M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$414.00K 10-Q · filed 2025-10-28 | -$3.71M derived: sum of 2 quarters · filed 2025-10-28 | -$5.83M 10-Q · filed 2025-10-28 | -$53.61M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$3.30M 10-Q · filed 2025-07-29 | -$5.42M 10-Q · filed 2025-07-29 | -$53.19M derived: sum of 3 quarters · filed 2026-02-25 | -$96.99M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$2.12M 10-Q · filed 2025-05-01 | -$49.89M derived: sum of 2 quarters · filed 2026-02-25 | -$93.69M derived: sum of 3 quarters · filed 2026-02-25 | -$135.72M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$47.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$91.57M derived: sum of 2 quarters · filed 2026-02-25 | -$133.60M derived: sum of 3 quarters · filed 2026-02-25 | -$163.40M 10-K · filed 2026-02-25 |
| 2023-09-30 | -$43.80M 10-Q · filed 2024-10-24 | -$85.83M derived: sum of 2 quarters · filed 2024-10-24 | -$115.63M 10-Q · filed 2024-10-24 | |
| 2023-06-30 | -$42.04M 10-Q · filed 2024-07-24 | -$71.83M 10-Q · filed 2024-07-24 | ||
| 2023-03-31 | -$29.80M 10-Q · filed 2024-05-01 | |||
| 2022-12-31 | -$125.11M 10-K · filed 2025-02-12 | |||
| 2021-12-31 | -$124.57M 10-K · filed 2024-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |